| __timestamp | Halozyme Therapeutics, Inc. | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 35942000 | 7751000 |
| Thursday, January 1, 2015 | 40028000 | 10251000 |
| Friday, January 1, 2016 | 45853000 | 9575000 |
| Sunday, January 1, 2017 | 53816000 | 10912000 |
| Monday, January 1, 2018 | 60804000 | 11049000 |
| Tuesday, January 1, 2019 | 77252000 | 11646000 |
| Wednesday, January 1, 2020 | 45736000 | 13265000 |
| Friday, January 1, 2021 | 50323000 | 25805000 |
| Saturday, January 1, 2022 | 143526000 | 35182000 |
| Sunday, January 1, 2023 | 149182000 | 94999000 |
| Monday, January 1, 2024 | 154335000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and profitability. Halozyme Therapeutics, Inc. and Viridian Therapeutics, Inc. have shown contrasting approaches over the past decade. From 2014 to 2023, Halozyme's SG&A expenses surged by over 300%, peaking in 2023. This reflects their aggressive expansion strategy. In contrast, Viridian's expenses grew at a steadier pace, increasing by approximately 1,200% over the same period, indicating a more controlled growth approach.
Despite Halozyme's higher absolute expenses, Viridian's rapid percentage increase suggests a dynamic shift in their operational strategy. Investors and stakeholders should consider these trends when evaluating the companies' financial health and strategic direction. As the biotech industry evolves, effective cost management will remain a key differentiator for success.
Selling, General, and Administrative Costs: Vertex Pharmaceuticals Incorporated vs Viridian Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Viatris Inc. and Halozyme Therapeutics, Inc.
Comparing SG&A Expenses: Sarepta Therapeutics, Inc. vs Viridian Therapeutics, Inc. Trends and Insights
Halozyme Therapeutics, Inc. and Apellis Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Halozyme Therapeutics, Inc. or ADMA Biologics, Inc.: Who Manages SG&A Costs Better?
Halozyme Therapeutics, Inc. or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Halozyme Therapeutics, Inc. vs Bausch Health Companies Inc.
R&D Spending Showdown: Halozyme Therapeutics, Inc. vs Viridian Therapeutics, Inc.
Selling, General, and Administrative Costs: Halozyme Therapeutics, Inc. vs MiMedx Group, Inc.
Comparing SG&A Expenses: Alpine Immune Sciences, Inc. vs Viridian Therapeutics, Inc. Trends and Insights
Breaking Down SG&A Expenses: Veracyte, Inc. vs Viridian Therapeutics, Inc.
BioCryst Pharmaceuticals, Inc. or Viridian Therapeutics, Inc.: Who Manages SG&A Costs Better?